The European Union-North American Clinical Trials in Alzheimer’s Disease Task Force (EU/US CTAD Task Force) has recently evaluated the status of blood-based AD biomarker and confirmed that (1) plasma Aβ levels accurately estimates the brain amyloid deposition, (2) plasma NfL levels correlates with neurodegeneration (although not specific for AD), and (3) plasma T-tau levels do not correlate with those of the CSF [110]. This evidence concerns the gene MAPT and Alzheimer disease.